Skip to main
  1. Stocks
  2. Ultragenyx Pharmaceutical
  3. Forecast
RARE

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Ultragenyx Pharmaceutical (RARE) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 21%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Ultragenyx Pharmaceutical is viewed positively because its core commercial base is proving resilient, with 3Q26 Dojolvi revenue of $30M versus $28M consensus and Evkeeza revenue of $24M versus $20M consensus, reinforcing that multiple franchises can still outperform expectations despite recent pipeline setbacks. Management also reiterated FY26 guidance and profitability in FY27 while outlining a 20% workforce reduction and capping FY27 R&D below $350M and SG&A below $375M, a sharper expense discipline that should materially improve operating leverage. Beyond cost cuts, the company has a deep rare-disease pipeline and a valuable commercial platform led by Crysvita, while the approval-related PRV windfall could generate about $400M in non-dilutive capital to support growth and de-risk execution.

Bears say

Ultragenyx Pharmaceutical is facing a weakened fundamental profile after the ASPIRE phase 3 failure for GTX-102 removed a major long-term growth driver and raised doubts about the company’s ability to convert pipeline assets into durable revenue. Analysts also trimmed FY26 Crysvita revenue to $502M, cut Dojolvi and Mepsevii trajectories, and reduced FY26 revenue by about $14M while noting the loss of UX701 and uncertainty around setrusumab leaves few clear pipeline bright spots. With management shifting toward expense reductions, focusing on existing products, and still targeting profitability around FY27, the stock may remain range bound as investors question whether the commercial portfolio can offset shrinking pipeline value.

Ultragenyx Pharmaceutical (RARE) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 21% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ultragenyx Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Ultragenyx Pharmaceutical (RARE) Analyst Forecast & Price Prediction

Get the latest Ultragenyx Pharmaceutical (RARE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ultragenyx Pharmaceutical (RARE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ultragenyx Pharmaceutical (RARE) Forecast

Analysts have given Ultragenyx Pharmaceutical (RARE) a Buy based on their latest research and market trends.

According to 19 analysts, Ultragenyx Pharmaceutical (RARE) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ultragenyx Pharmaceutical (RARE)


Ultragenyx Pharmaceutical (RARE) Analyst Forecast & Price Prediction

Get the latest Ultragenyx Pharmaceutical (RARE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ultragenyx Pharmaceutical (RARE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RARE stock data and trends